A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation study to evaluate the safety and tolerability of KN035
in Japanese patients with advanced and metastatic solid tumor. The dose escalation will
follow the widely used 3+3 design.